Beigene Ltd (NASDAQ:BGNE) insider Xiaodong Wang sold 5,000 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $280.42, for a total value of $1,402,100.00. Following the completion of the transaction, the insider now directly owns 7,201,009 shares in the company, valued at $2,019,306,943.78. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Xiaodong Wang also recently made the following trade(s):
- On Thursday, September 17th, Xiaodong Wang sold 5,000 shares of Beigene stock. The shares were sold at an average price of $260.27, for a total value of $1,301,350.00.
- On Monday, August 10th, Xiaodong Wang sold 4,000 shares of Beigene stock. The shares were sold at an average price of $211.06, for a total value of $844,240.00.
- On Tuesday, July 7th, Xiaodong Wang sold 6,000 shares of Beigene stock. The shares were sold at an average price of $200.00, for a total value of $1,200,000.00.
NASDAQ:BGNE traded up $0.81 during midday trading on Tuesday, hitting $281.46. 233,252 shares of the stock were exchanged, compared to its average volume of 294,218. Beigene Ltd has a one year low of $114.41 and a one year high of $284.45. The company has a market capitalization of $25.44 billion, a price-to-earnings ratio of -13.73 and a beta of 1.31. The business has a 50-day moving average price of $244.37 and a two-hundred day moving average price of $189.94. The company has a current ratio of 6.15, a quick ratio of 6.09 and a debt-to-equity ratio of 0.11.
Beigene (NASDAQ:BGNE) last announced its earnings results on Thursday, August 6th. The company reported ($4.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.78) by $0.47. Beigene had a negative return on equity of 72.94% and a negative net margin of 620.47%. The firm had revenue of $65.64 million for the quarter, compared to analysts' expectations of $50.10 million. Sell-side analysts forecast that Beigene Ltd will post -17.38 EPS for the current fiscal year.
A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Beigene from a "buy" rating to a "hold" rating in a research note on Friday, August 21st. ValuEngine upgraded Beigene from a "hold" rating to a "buy" rating in a research note on Saturday, September 5th. Morgan Stanley lifted their target price on Beigene from $235.00 to $241.00 and gave the company an "overweight" rating in a research note on Monday, August 10th. SVB Leerink lifted their target price on Beigene from $207.00 to $210.00 and gave the company an "outperform" rating in a research note on Wednesday, June 3rd. Finally, LADENBURG THALM/SH SH lifted their target price on Beigene from $232.00 to $268.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Beigene has a consensus rating of "Buy" and an average target price of $219.11.
A number of institutional investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC acquired a new position in Beigene in the second quarter worth approximately $1,194,000. Mitsubishi UFJ Trust & Banking Corp grew its position in Beigene by 28.2% in the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 37,744 shares of the company's stock worth $7,111,000 after buying an additional 8,301 shares during the last quarter. Two Sigma Securities LLC acquired a new position in Beigene in the second quarter worth approximately $234,000. Principal Financial Group Inc. grew its position in Beigene by 46.3% in the second quarter. Principal Financial Group Inc. now owns 4,494 shares of the company's stock worth $846,000 after buying an additional 1,422 shares during the last quarter. Finally, Handelsbanken Fonder AB acquired a new position in Beigene in the second quarter worth approximately $2,261,000. Hedge funds and other institutional investors own 56.12% of the company's stock.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Read More: Sell-Side Analysts
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Stocks You Can Count On During Any Crisis
Depending on how you look at it, the economic outlook is getting cloudier or clearer.
The argument for a cloudy economy is easy to make. Multiple times of day we hear about more Americans testing positive for the novel coronavirus. The worldwide number of positive tests exceeds one million. And unfortunately, it will go higher. We just don’t know by how much.
But there are two parts to this ongoing situation. The first is the real-time science experiment as the world attempts to flatten the curve. The other is the very real economic impact. And the numbers of the economic carnage are coming in faster than any significant evidence of a flattening curve.
The number of unemployed now exceeds six million and will only rise. The government is throwing everything including the kitchen sink at the problem. But it’s an experiment in real-time. We won’t know the results for some time.
But even while we wait for a new normal to return, there are ways for you to profit. There are companies that are keeping our economy going now, and have a business model that sets them up well for success after the pandemic is over.
View the "8 Stocks You Can Count On During Any Crisis".